<DOC>
	<DOCNO>NCT02264015</DOCNO>
	<brief_summary>Incidence visual phenomenon , heart rate rest , safety ( particular emphasis QT analysis ECGs ) , pharmacokinetic parameter</brief_summary>
	<brief_title>Pharmacodynamic Effects , Safety Tolerability Cilobradine , Healthy Male Female Volunteers , With Intra-individual Comparison Moxifloxacin Subset Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test 1.1 No find deviate normal clinical relevance 1.2 No evidence clinically relevant concomitant disease 2 . Age ≥21 Age ≤55 year 3 . BMI ≥18.5 BMI &lt; 30 kg/m2 ( Body Mass Index ) 4 . Resting Heart rate ( HR ) ( 10 min . supine position ) equal 60 bpm 5 . Females : postmenopausal hysterectomy ( plus negative pregnancy test ) 6 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , ophthalmological , hormonal disorder 2 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 3 . History relevant orthostatic hypotension , faint spell blackouts 4 . Chronic relevant acute infection 5 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 6 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 7 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 8 . Participation another trial investigational drug within two month prior administration trial 9 . Smoker ( 10 cigarette 3 cigar 3 pipes/day ) 10 . Inability refrain smoke trial day 11 . Alcohol abuse 12 . Drug abuse 13 . Blood donation ( 100 mL within four week prior administration trial ) 14 . Excessive physical activity ( within one week prior administration trial ) 15 . Any laboratory value outside reference range clinical relevance . Exclusion criterion specific study : 16 . Subjects increase risk development cardiac arrhythmia ( e.g . family history long QT syndrome sudden cardiac death )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>